A phase I/II trial of epirubicin and docetaxel in locally advanced breast cancer (LABC) on 2-weekly or 3-weekly schedules: NCIC CTG MA.22

Maureen Elizabeth Trudeau1*, Judith-Anne W. Chapman2, Baoqing Guo3, Mark J. Clemons4, Rebecca A. Dent1, Roberta A. Jong1, Harriette J. Kahn1, Kathleen I. Pritchard1, Lei Han2, Patti O’Brien2, Lois E. Shepherd2 and Amadeo M. Parissenti3

Abstract
This phase I/II neoadjuvant trial (ClinicalTrials.gov identifier NCT00066443) determined maximally-tolerated doses (MTD), dose-limiting toxicities, response-to-therapy, and explored the role of novel response biomarkers. MA.22 accrued T3N0, any N2 or N3, and T4 breast cancer patients. Treatment was 6 cycles of 3-weekly (Schedule A; N = 47) or 8 cycles of 2-weekly (Schedule B; N = 46) epirubicin/docetaxel chemotherapy in sequential phase I/II studies, with growth factor support. In phase I of each schedule, MTDs were based on DLT. In phase II, clinical responses (CR/PR) and pathologic complete responses (pCR) were assessed. Tumor biopsy cores were obtained pre-, mid-, and post-treatment: 3 for pathologic assessment; 3 for microarray studies. DLT for Schedule A was febrile neutropenia at 105 mg/m² epirubicin and 75 mg/m² docetaxel; for schedule B, it was fatigue at 75 mg/m² for both agents. Phase II doses were 90 mg/m² epirubicin/75 mg/m² docetaxel for Schedule A and 60 mg/m² (both agents) for Schedule B. Schedule A CR/PR and pCR rates were 90 and 10 %, with large reductions in tumor mRNA content and integrity following treatment; Schedule B results were 93 and 0 %, with smaller reductions in RNA quality. Pre-treatment expression of several genes was associated with clinical response, including those within a likely amplicon at 17q12 (ERBB2, TCAP, GSDMB, and PNMT). The combination regimens had acceptable toxicity, good clinical response, induction of changes in tumor RNA content and integrity. Pre-treatment expression of particular genes was associated with clinical responses, including several near 17q12, which with ERBB2, may better identify chemoresponsiveness.

Keywords: LABC, Phase I/II, Epirubicin, Docetaxel, Microarray, Response biomarkers

Background
LABC is traditionally defined as stage IIB (T3N0) and Stage IIIA/B/C from the TMN classification (Chia et al. 2008; Hortobagyi et al. 1995). LABC represents 10–15 % of breast cancer cases, with 5-year survival of 30–42 % of patients (Canadian Cancer Society et al. 2012), a significant portion of whom will have metastatic disease. However, a small subset of women who receive neoadjuvant chemotherapy and achieve a pathologic complete response (pCR), defined as no microscopic residual invasive disease following treatment, have a significantly improved 5-year disease-free survival (DFS) rate of about 87 %, and 5-year overall survival (OS) rates near 90 % (Kuerer et al. 1999). pCR rates have thus become an accepted surrogate measure for favorable long-term outcomes after neoadjuvant chemotherapy (Mieog et al. 2007; Sinclair and Swain 2010; Specht and Gralow 2009). While pCR appears to be associated with ultimate DFS and OS outcomes, patients with certain tumor subtypes have substantially lower pCR rates,
but can still have favorable outcomes (Carey et al. 2007; Esserman et al. 2012; Rouzier et al. 2005). Early biomarkers, preferably before systemic therapy, would significantly enhance patient care (Carey et al. 2007; Esserman et al. 2012; Carey and Winer 2014; Cortazar et al. 2014; Houssami et al. 2012).

A number of commonly used anthracycline and taxane containing regimens have been studied in combination (TAC) or in sequence [dd(AC-P), AC-weekly P, FEC-D, AC-D] (Aigner et al. 2011; Gandhi et al. 2015; Raza et al. 2009). (Where T or D = docetaxel; P = paclitaxel; A = doxorubicin; C = cyclophosphamide; F = 5 fluorouracil; dd = dose-dense). However, optimal doses and schedules for anthracycline/taxane combination regimens have not been established for epirubicin and docetaxel. We examined the efficacies and toxicities associated with epirubicin/docetaxel combination chemotherapy at various doses and schedules for women with LABC. We also conducted exploratory tumor genome profiling studies for prospective biomarkers of response to the regimens.

**Patients and methods**

**Study design**

The NCIC Clinical Trials Group MA.22 is a non-randomized phase I/II clinical trial (ClinicalTrials.gov identifier NCT00066443) to determine optimal dosing regimens for docetaxel/epirubicin combination chemotherapy in women with locally advanced or inflammatory breast cancer. The protocol was approved by Health Canada and local Ethics Review Boards; patients provided written, informed consent.

Escalating doses of epirubicin and docetaxel were administered to patients in either a standard q3 weekly (Schedule A) or dose dense q2 weekly (Schedule B) regimen. Doses for Schedule A were 75 mg/m² IV of docetaxel and 75, 90, 105, or 120 mg/m² IV of epirubicin (with pegfilgrastim 6 mg primary prophylaxis sc per cycle on day 2). Doses for both docetaxel and epirubicin in Schedule B were 50, 60, and 70 mg/m² IV (with pegfilgrastim support). For each schedule, phase I was dose finding for phase II. Cohorts of three patients were recruited at each dose level with three additional patients recruited if a dose limiting toxicity (DLT) was observed. If two or more DLTs were noted, the dose level was declared as the Maximum Tolerated Dose (MTD) and the phase II component of the trial was opened at the dose level below the MTD. DLTs may have been hematological, non-hematological, or related to the inability to deliver therapy and are defined in Table 1. None of the patients received trastuzumab initially and HER2+ patients were not enrolled on study, once trastuzumab funding became available. The microarray data have been uploaded to the Gene Expression Omnibus (GEO) portal (accession number GSE66999). This data can be found at: http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?token=irezcewdvczzyt&acc=GSE66999.

**Patients**

Eligible patients had histologically confirmed invasive adenocarcinoma of the breast, which met the following criteria: T3N0, any N2 or N3, or inflammatory carcinoma. Patients had no clinical or radiological evidence of distant disease and no previous treatment for breast cancer. Age was >16 years, with ECOG status of 0–2, and adequate bone marrow, hepatic and renal function. Left ventricular ejection fraction must have been within the institutional norm.

**Study oversight**

Data were collected, managed, and analyzed by the NCIC CTG. The NCIC CTG Data Safety Monitoring Committee reviewed study conduct, safety, and efficacy on a 6-monthly basis. The trial committee made the decision to publish the results. Manuscript writing was undertaken entirely by the first author, coauthors, and staff at the NCIC CTG central office, who vouch for the fidelity of the study and the data.

**Study endpoints**

The primary objective of the phase I portion of each schedule was to identify DLTs, the MTD, and the dose for the q3 weekly and q2 weekly regimens. Phase I secondary objectives were to conduct microarray and immunohistochemical assessments of biomarker sensitivity/resistance to epirubicin and docetaxel.

| Toxicities | Schedule A (N = 47) | Schedule B (N = 46) |
|------------|---------------------|---------------------|
| Febrile neutropenia | 6 (DLT Phase I) | 0 |
| Fever | 1 | 0 |
| Infections without neutropenia | 2 | 1 |
| Fatigue | 1 | 7 (DLT Phase I) |
| Muscle weakness | 0 | 1 |
| Epistaxis | 0 | 1 |
| Bleeding | 1 | 0 |
| Pain | 1 | 5 |
| Cardiac LVF | 0 | 1 |
| Nausea/vomiting/diarrhea | 6 | 1 |
| Dizziness/syncope/dehydration | 4 | 0 |
| Neuropathy—sensory | 0 | 3 |

* Toxicities were determined by using NCI Common Toxicity Criteria V2.0.
The primary objective of phase II for both schedules was to evaluate clinical response rates at selected dose levels. Clinical response was defined as complete clinical response (CR; absence of disease by palpation post-treatment) or partial response (PR; patients with caliper measurements exhibiting a decrease in tumor volume ≥50 %). Patients with tumor volume decreases <50 % were considered to have stable disease (SD). If tumors increased in size, then patients had progressive disease (PD).

In phase II, secondary objectives were to examine pCR rates (pathologic absence of tumor in the breast and axillary lymph nodes at primary surgery), duration of response (time from CR or PR until progression), toxicities by NCI Common Toxicity Criteria V2.0, biomarker assessments of response to therapy, and time to distant metastasis (defined as time from registration to the first evidence of recurrent disease) and survival (time to death). The pCR rate was too low for pCR to be used as an endpoint for biomarker assessments so clinical response was used.

**Tumor core biopsies and isolation of tumor RNA**

Six image-guided core biopsies of tumors were obtained pre-treatment; mid-treatment, at 3 (q3 weekly) or 4 (q2 weekly) cycles of chemotherapy; and post-treatment at 6 (q3 weekly) or 8 (q2 weekly) cycles (Additional file 1: Appendix S1). Three biopsies at each time point were stored in formalin for histological and immunohistochemical studies, while three were flash frozen and stored in liquid nitrogen (−190 °C). For RNA isolation, the methods were as previously described (Parissenti et al. 2010). Frozen biopsies were homogenized in RLT buffer and the RNA isolated using a Qiagen RNeasy™ RNA isolation kit (Qiagen Inc., Toronto, ON, Additional file 1: Appendix S1). Samples (in 35 μl of RNase-free water) were then stored at −80 °C. RNA quality was assessed by applying 1 μl of the preparation onto Caliper™ RNA nanochips (Caliper Technologies, Hopkinton, MA) and using capillary electrophoresis on an Agilent 2100 Bioanalyzer to resolve component RNAs. The Bioanalyzer software generated an RNA integrity number (RIN) between 1 and 10, where 10 represents highly intact RNA and 1 represents highly degraded RNA.

**Microarray profiling of gene expression**

High RNA quality (RIN ≥5) was necessary for microarray assessment, and treatment frequently reduced mid-treatment RIN to levels <5. A surrogate endpoint of mid-treatment RIN (<5, ≥5) was utilized to examine baseline genes associated with RIN level, in addition to the examinations of genes associated with clinical response. High throughput gene expression studies using Agilent 4 x 44 k human genome arrays (27,958 human Entrez gene probes representing almost the entire protein-coding genome) were conducted on RNA preparations from pre- and mid-treatment tumor samples with RIN ≥5.0. The protocol used is described in Additional file 1: Appendix S1.

**Histological and Immunohistochemical Characterization of Tumors**

The histological features as well as extent of tumor in the core biopsies were evaluated on H&E sections. Pre-treatment, the expression of cell surface receptors were assessed by immunohistochemical microscopy: estrogen receptor (ER; clone 6G11, Novocastra), progesterone receptor (PR; clone 16, Novocastra), Her2/Neu receptor (HER2; TAB 250, ZYMED), and topo2 (clone SWT3D1, DAKO) (Parissenti et al. 2010).

**Statistical analysis**

Reporting is by Schedule for all analyses. All patients who received at least one dose of study treatment were included in the safety reports, subdivided by schedule and phase. Phase II DFS and OS were described with Kaplan–Meier plots. Biomarkers were assessed for all patients; ER, PR, Her2, and Topo2 immunohistochemical assessments were used to characterize tumors.

Full genome profiling was conducted using Agilent microarrays, where RNA was of sufficient quantity and quality (RIN ≥5) for profiling. Some RNAs were not available for Agilent gene profiling due to their use on prior microarrays of inferior quality, such that all patient tumors could not be profiled. The quality of the prior microarray data was insufficient to combine with the Agilent data. Exact Fisher tests (categorical factors) and Wilcoxon signed-rank tests (continuous factors) were used to compare the patient and tumor characteristics for patients with, or without, Agilent assessments. BRB array tools (version 4.2.1) were used to examine baseline gene expressions for exploratory identification of genes associated with response to epirubicin/docetaxel chemotherapy (class prediction), where response was defined in separate assessments as clinical response, and as RIN (<5, ≥5) at mid-treatment. We examined gene expression changes for patients who had both pre- and mid-treatment arrays with RIN ≥5.0 (class comparisons), to examine the association of gene expression changes with hormone receptor status (ER/PR), HER2, Topo2, and treatment dose (ANOVA to examine fixed effects; paired t-tests to examine differentially expressed genes). P values <0.001 were considered significant; we considered a false discovery rate (FDR) of <0.1.
Results
MA.22 accrued 93 patients from February 25, 2003 to June 9, 2009; 47 to Schedule A, 46 had tumor blocks and 46 to Schedule B, all of whom had tumor blocks (CONSORT diagram, Fig. 1 outlines enrollment by schedule). Patient and tumor characteristics data are presented by schedule in Table 2. Five Schedule A and 11 Schedule B patients did not have Agilent assessments; PR levels were higher in those not assessed (p = 0.04; 0.01, respectively).

The phase I MTD for the three weekly regimen (Schedule A) was 120 mg/m² epirubicin and 75 mg/m² docetaxel, with the phase II portion conducted at 105 and 75 mg/m², respectively. The clinical response rate for Schedule A was 28/31 (90.3 %), with median duration of response of 2 years (range 0.1–5.6) and 3/31 (9.7 %) pCR. For the dose dense (2 weekly) regimen (Schedule B), the MTD was 75 mg/m² for both agents. In the phase 2 portion, patients received 60 mg/m² of both drugs; the clinical response rate was 28/30 (93.3 %) with median duration of response of 0.2 years (range 0.1–3.9) and no pCR.

Table 1 outlines grade 3 or 4 toxicities for all patients. The DLT for Schedule A was febrile neutropenia, while for Schedule B, DLT was fatigue. None of the toxicities were unexpected for the combination of epirubicin and docetaxel.

Disease-free survival
Recruitment for Schedule B began after that for Schedule A: median follow-up for Schedule A was 7.3 years (95 % CI 6.6–7.6), with 50 months DFS 59 % (95 % CI 39–74 %; Additional file 1: Figure S1A); Schedule B median follow-up was 3.6 years (95 % CI 3.5–4.0), with 50 months DFS 60 % (95 % CI 31–80 %; Additional file 1: Figure S1B). Time to distant metastases and overall survival will not be reported here.

RNA integrity (RIN) and pCR
Tumor RNA integrity decreased significantly (p < 0.001) following chemotherapy. For Schedule A, phase II patients from a pre-treatment mean of 5.4 (95 % CI 5.1–5.7) to mid-treatment 1.9 (95 % CI 1.6–2.2) and post-treatment 1.9 (95 % CI 1.5–2.3) (Additional file 1: Table S1). Mean tumor RIN values for Phase II patients in Schedule B also significantly decreased (p < 0.0001) from pretreatment 5.8 (95 % CI 5.5–6.1) to mid-treatment 4.3 (95 % CI 4.0–4.6) and post-treatment 2.9 (95 % CI 2.6–3.2). The effect of treatment on tumor RNA integrity is evident in scatter plots of maximum tumor RIN versus tumor RNA concentration for Schedule A and B patients prior to and during treatment (Additional file 1: Figure S2), where treatment resulted in a clustering of patient tumor samples to regions of low RIN and low RNA concentration values. This occurred for both patients that achieved a pCR and those that did not.

Figure 2 depicts maximum tumor RIN by schedule, dose level, and treatment period for all patients accrued to that schedule. Schedule A patients (Fig. 2a) did not have significantly different pre-treatment RIN, mid- and post-treatment RIN (p = 0.40; 0.24; 0.17, respectively). Schedule B patients (Fig. 2b) had different RIN pre-treatment (p = 0.06) and post-treatment (p = 0.03), although not at mid-treatment (p = 0.29). The composite of all patients accrued to two MA.22 schedules is shown in Fig. 2c and summarized in Additional file 1: Table S1.

Analysis of gene expression in tumor core biopsies
In all Schedule A patients for whom tumor RNA quality pre-treatment was sufficient in quantity and quality for DNA microarray analysis, 10 had a complete clinical response (CR), 30 had a partial response (PR), and 1 had stable disease (SD). No Schedule A patients exhibited disease progression (PD). Eleven genes had significantly altered expression in the tumors of patients who exhibited a CR in Schedule A compared to patients that had a PR, SD, or PD or were differentially expressed between 27 patients with tumor RIN <5 and 14 patients with tumor RIN ≥5 (Table 3 Schedule A for clinical response (Ammann et al. 2013; Benusiglio et al. 2006; Boucquy et al. 2006; Coon et al. 2002; Katoh 2004; Marshall et al. 1979; Nicholas et al. 2002; Pritchard et al. 2006; Qiu et al. 2014; Rauch et al. 2006; Saeki et al. 2009; Staaf et al. 2010); Additional file 1: Table S2 for RIN (Wang et al. 2010); Additional file 1: Table S2 for RIN (Wang et al. 2011; Yosten et al. 2012; Zudaire et al. 2008); and Fig. 3a). In Schedule B, the pre-treatment expression of 9 tumor genes has associations with clinical response (3 CRs, 27 PR, 4SD, 1PD) or were differentially expressed between 18 patients with tumor RIN <5 and 17 patients with tumor RIN ≥5 (Table 3 Schedule B for clinical response (Biaoxue et al. 2012; Cagnoni and Tamagnone 2014; Campbell et al. 2013; Malik et al. 2014; Sakwe et al. 2011; Yuan et al. 2006; Zhang et al. 2013); Additional file 1: Table S2 for RIN (Araki and Milbrandt 2000; Feng et al. 2006; Inuzuka et al. 2005; Liedtke et al. 2007; Salzman et al. 2011); and Fig. 3b). The numbers of genes associated with change in matched pre- and mid-treatment samples and with immunohistochemical biomarkers or dose greatly exceeded the sample size so are not reported here.

Discussion
A clinical CR or PR after neoadjuvant chemotherapy are relatively common in LABC patients; however, despite these responses there is still frequently residual disease found within the breast or axilla post-treatment (Guarneri et al. 2006). While pCR rates have
been associated with a survival benefit from treatment, such a benefit has not been shown for patients with LABC (Mieog et al. 2007; Sinclair and Swain 2010; Specht and Gralow 2009). Indeed, pCR rates remain low in patients with LABC, especially those patients who have ER+/Her2- disease, i.e. the majority of breast cancer patients (Kuerer et al. 1999; Guarneri et al. 2006; Liu et al. 2010). In this study, while more than 90% of patients had either a CR or PR, less than 10% of patients exhibited a pCR. It is likely that pCR underestimates the effects of chemotherapy in certain patients.

**Phase I Q3 Weekly**

| Number of Patients (n) | Epirubicin (mg/m²) | Docetaxel (mg/m²) |
|------------------------|--------------------|-------------------|
| 3                      | 75                 | 75                |
| 6                      | 90                 | 75                |
| 4                      | 105                | 75                |
| 3                      | 120                | 75                |

**Phase II Q3 Weekly**

| Number of Patients (n) | Epirubicin (mg/m²) | Docetaxel (mg/m²) |
|------------------------|--------------------|-------------------|
| 31                     | 105                | 75                |

**Phase I Q2 Weekly**

| Number of Patients (n) | Epirubicin (mg/m²) | Docetaxel (mg/m²) |
|------------------------|--------------------|-------------------|
| 4                      | 50                 | 50                |
| 3                      | 60                 | 60                |
| 6                      | 70                 | 70                |
| 3                      | 75                 | 75                |

**Phase II Q2 Weekly**

| Number of Patients (n) | Epirubicin (mg/m²) | Docetaxel (mg/m²) |
|------------------------|--------------------|-------------------|
| 30                     | 60                 | 60                |

*Fig. 1* CONSORT diagram
In this study, we provide hypothesis generating evidence for additional biomarkers that may help predict a long-term favorable response to chemotherapy or monitor response to chemotherapy in real time. Chemotherapy treatment was found to be associated with a reduction in tumor RNA content and RNA integrity. Her2-overexpressing breast tumors are known to be highly clinically responsive to chemotherapy (Guarneri et al. 2006; von Minckwitz et al. 2012). Interestingly, for all patients undergoing microarray analysis in our study, in the absence of Herceptin, HER2/ERBB2 transcripts were >fivefold higher in patients that had a CR after chemotherapy compared to patients with a PR, SD, or PD. The expression of 3 additional genes within 17q12 (GSDMB, PNMT, TCAP) had 3.7- to 13.3-fold higher expression in CR patients (Table 3 Schedule A). This higher expression may be related to an amplification of 17q12 in responding tumors. Amplification of 17q12–q21 is common in ERBB2 overexpressing breast cancers, particularly in a 280 kb region that includes the 3 additional genes identified above (Kauraniemi and Kallioniemi 2006). Thus, in addition to HER2/ERBB2, our data suggests that the expression of all four genes is associated with a CR post-chemotherapy. As shown in the heat map depiction of patient gene expression data, some patients with CRs did not exhibit HER2 overexpression, but exhibited overexpression of other genes associated with a CR, including SINGLEC11, ONECUT2, and/or BTN2A2 (Fig. 3a).

The above overexpressed genes within 17q12 reside on chromosome 17 in the following order: TCAP, PNMT, ERBB2, and GSDMB. In this study, their tumor expression was 3.7-, 13.3-, 5.6-, and 4.0-fold higher in clinical responders, respectively. This suggests that the amplification may be centered on PNMT rather than ERBB2, or the amplification has a greater effect on PNMT transcription. The PNMT amplification or overexpression could be a more sensitive or reliable biomarker of clinically chemoresponsive breast cancer than Her2 overexpression. Moreover, the additional genes identified in this study may improve our ability to predict clinical response to chemotherapy.

The ability of these additional genes to predict or affect clinical response to chemotherapy may be related to their roles in cells. Gsadermin-B (the GSDMB gene product) has been shown to promote tumor formation, invasion, and metastasis in mouse xenograft models and the expression

| Table 2 Patient and tumour characteristics and response by whether patient’s tumour assessed by agilent microarray |
|---------------------------------|----------------|----------------|----------------|----------------|
| Included phase I/II | Schedule A | N with banked tumour = 46 | Schedule B | N with banked tumour = 46 |
| | Yes (N = 41) | No (N = 5) | Total (N = 46) | P value | Yes (N = 35) | No (N = 11) | Total (N = 46) | P value |
| Clinical N stage | N1 | 17 | 1 | 18 | 8 | 2 | 10 | 1.0000 | 0.0000 |
| | N2 | 15 | 3 | 18 | 24 | 5 | 29 | 0.6983 | 0.1074 |
| | N3 | 3 | 0 | 3 | 2 | 3 | 5 | 0.3405 | 0.7088 |
| | NX | 6 | 1 | 7 | 1 | 0 | 1 | 0.3405 | 0.7088 |
| | N0 | 0 | 0 | 0 | 0 | 1 | 1 | 0.3405 | 0.7088 |
| Clinical T stage | T2 | 2 | 0 | 2 | 1 | 0 | 1 | 0.3405 | 0.7088 |
| | T3 | 13 | 1 | 14 | 18 | 5 | 23 | 0.3405 | 0.7088 |
| | T4 | 26 | 4 | 30 | 16 | 4 | 20 | 0.3405 | 0.7088 |
| | T1 | 0 | 0 | 0 | 0 | 1 | 1 | 0.3405 | 0.7088 |
| | TX | 0 | 0 | 0 | 1.0000 | 0 | 1 | 1 | 0.2185 |
| Age | Median | 48.5 | 47.8 | 41.8 | 45.4 | 0.3061 | 0.7088 |
| | Range | (27.4, 72.3) | (44.1, 72.2) | (28.2, 65.2) | (27.5, 60.1) | 0.1919 | 0.7088 |
| ER | Median | 40 | 100 | 0 | 100 | 0.3909 | 0.1919 |
| | Range | (0, 100) | (0, 100) | (0, 100) | (0, 100) | 0.04134 | 0.01362 |
| PR | Median | 0 | 60 | 0 | 100 | 0.06909 | 0.5997 |
| | Range | (0, 100) | (0, 100) | (0, 100) | (0, 100) | 0.4537 | 0.1411 |
| Her2 | Median | 0 | 0 | 0 | 0 | 80 | 100 | 0.1411 |
| | Range | (0, 100) | (0, 100) | (1, 00) | (1, 00) | 0.9887 | 0.9887 |

P value is based on Fisher’s exact test for categorical factors and Wilcoxon signed-rank test for continuous.
Fig. 2  

a Schedule A maximum RIN by dose level and treatment time.  
b Schedule B maximum RIN by dose level and treatment time.  
c Schedule A and B maximum RIN by dose level and treatment time.
of gasdermin-related genes was correlated with reduced survival in breast cancer patients (Hergueta-Redondo et al. 2014). Thus, the poor prognosis associated with HER2 overexpression in breast cancer (and its relationship to enhanced clinical response to chemotherapy) may also be related to the overexpression of Gasdermin B. Titin-Cap (the TCAP gene product) blocks the secretion of myostatin, a transforming growth factor β (TGF-β) family member that negatively regulates cell growth (Nicholas et al. 2002). Since myostatin promotes apoptosis in breast tumor cells (Liu et al. 2013), the overexpression of Titin-Cap would be expected to strongly promote breast tumor proliferation. This would render cells more sensitive to killing by chemotherapy agents that target rapidly dividing tumors. It is unclear how PNMT (phenylethanolamine N-methyltransferase), which catalyzes the conversion of norepinephrine to epinephrine, might play a role in chemotherapy response. Two other genes whose expression pre-treatment was significantly elevated in chemoresponsive tumors (BTN2A2 and ONECUT2) would be expected to improve clinical response to chemotherapy, since the enhanced expression of the former gene inhibits AKT-dependent survival pathways and is associated with improved patient prognosis (Ammann et al. 2013), while the latter gene is a known tumor suppressor gene (Rauch et al. 2006).

### Table 3 Genes whose expression pretreatment is associated with clinical response to chemotherapy as measured by calipers

| Gene     | Fold change CR/ (PR + SD + PD) | Fold change CR/PR | Role and references                                                                 | Chromosomal location |
|----------|--------------------------------|-------------------|--------------------------------------------------------------------------------------|----------------------|
| **Schedule A** |                                 |                   |                                                                                      |                      |
| PGM2     | N.S.                           | −2.0              | Phosphoglucomutase-2; deletion mutation in cervical cancer (Marshall et al. 1979)     | 4p14                 |
| GSDMB    | +4.0                           | +3.8              | Gasdermin B, overexpressed in gastric and esophageal cancers; expressed in proliferating cells, but not differentiated cells; site of recombination hotspot around ERBB2 (Katoh 2004; Saeki et al. 2009) | 17q12               |
| ERBB2    | +5.6                           | +5.2              | ERBB2; Highly correlated to clinical response in breast cancer (Coon et al. 2002; Pritchard et al. 2006) | 17q12               |
| FAM114A1 | −2.0                           | −2.0              | Also called NOXP20; protein overexpressed in the nervous system (Boucquey et al. 2006) | 4p14                 |
| PNMT     | +13.25                         |                    | Phenylethanolamine N-methyltransferase; associated with ERBB2 amplification, catalyzes synthesis of epinephrine to norepinephrine (Staaf et al. 2010) | 17q12               |
| BTN2A2   | +2.2                           |                    | Butyrophilin; Inhibits AKT pathway; expression in epithelial and ovarian cancer associated with higher infiltrating T cells; associated with better prognosis (Ammann et al. 2013) | 6p22                 |
| TCAP     | +3.7                           |                    | Titin-Cap protein; associated with the ERBB2 amplicon in breast cancer; associated with ERBB2 genetic polymorphisms associated with gastric cancer; associated with growth factor myostatin (Benusiglio et al. 2006; Nicholas et al. 2002; Qiu et al. 2014) | 17q12               |
| ONECUT2  | +4.9                           |                    | Tumor suppressor gene repressed in lung cancer; promotes growth of liver cells (Rauch et al. 2006) | 18q21               |
| **Schedule B** |                                 |                   |                                                                                      |                      |
| PSTK     | +2.7                           |                    | Phosphoseryl tRNA Sec Kinase; involved in selenocysteine biosynthesis; important for ribosomal protein synthesis (Yuan et al. 2006) | 10q                  |
| ANXA6    | −1.8                           |                    | Annexin A6; activates NF-κB survival pathway, contributes to invasiveness in breast cancer cells; correlates with poor survival/mets in lung cancer (Biaoxue et al. 2012; Campbell et al. 2013; Sakwe et al. 2011) | 5q32                 |
| LINGO1   | −3.1                           |                    | LINGO 1 protein; promotes apoptosis (Zhang et al. 2013) | 15q24                |
| SEMA4D   | +33                            |                    | Semaphorin 4A; binds to Plexin B1, which physically associates with and activates ERBB2 (Cagnoni and Tamagnone 2014; Malik et al. 2014) | 1q22                 |
Fig. 3  a Schedule A heat map of patient gene expression data. b Schedule B heat map of patient gene expression data
This study has limitations due to its small sample size; however, evidence is provided for two schedules of epirubicin and docetaxel therapy with hypothesis generating evidence for the potential value of the quality assurance measure RIN. Reductions of RIN that prevent microarray assessments after chemotherapy may in fact be a surrogate for clinical responsiveness to therapy. While most (≥90%) of MA.22 patients had a clinical response, the proportion of patients with mid-treatment RIN that was too low for microarray assessment was much lower. However, neither clinical response nor RIN reduction was reflective of the low pCR rates seen here, which is the context in which identified genes may be useful for exploration elsewhere.

Conclusion
In summary, the MA.22 clinical trial revealed that epirubicin/docetaxel combination chemotherapy can be delivered in LABC patients with acceptable toxicity. This regimen can, in some patients, induce strong reductions in tumor RNA integrity that are associated with post-treatment pCRs. Elevated expression of specific genes within 17q12 near the HER2/ERBB2 locus and other genes were found to be associated with a complete clinical response to epirubicin/docetaxel chemotherapy. These genes could represent new targets for drug development that could improve clinical response to future regimens.

Additional file

Authors’ contributions
Study conception and design: MET, JWC, KIP, LES, AMP. Study collection and assembly of data: MET, JWC, BG, MJC, RAD, RAJ, HJK, KIP, PO'B, LES, AMP. Study data analysis: MET, JWC, BG, RAD, HJK, KIP, LH, PO'B, LES, AMP. Manuscript writing and final approval: MET, JWC, BG, MJC, RAJ, HJK, KIP, LH, PO'B, LES, AMP. All authors read and approved the final manuscript.

Author details
1 Sunnybrook Odette Cancer Centre, University of Toronto, 2075 Bayview Avenue, Toronto, ON M4N 3M5, Canada. 2 NCIC Clinical Trials Group, Queen’s University, 10 Stuart Street, Kingston, ON K7L 3N6, Canada. 3 Advanced Medical Research Institute of Canada (AMRIC), 41 Ramsey Lake Road, Sudbury, ON P3E 5J1, Canada. 4 The Ottawa Hospital Cancer Centre, University of Ottawa, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada.

Acknowledgements
The authors wish to acknowledge the contributions of Jianfeng Xu and Keyue Ding to the analysis of baseline gene expression correlation with clinical response or changes in RIN using BRB tools.

Competing interests
The following authors have no competing interests to disclose: JWC, MJC, RAD, RAJ, HJK, LH, PO'B, and LES, shareholders—RNA Diagnostic Inc.: MET, BG and AMP; research funding: AMP has received research funding from RNA Diagnostics Inc.; patent or intellectual property interest: BG and AMP with RNA Diagnostic Inc.; leadership roles: AMP has a leadership role with RNA Diagnostic Inc. as Chief Scientific Officer; travel, accommodations or expenses to disclose: AMP with RNA Diagnostic Inc.; consultant/advisory roles: KIP with Sanofi-Aventis, AstraZeneca, Pfizer, Roche, Amgen, Novartis, GlaxoSmithKline, Boehringer Ingelheim, Genomic Health and Eisai and MET with Astellas/Medivation and RNA Diagnostics Inc.

Financial support
Supported by the NCIC Clinical Trials Group through grant support from the Canadian Cancer Society Research Institute, AMGEN Canada Inc., AVENTIS Pharma Inc., PFIZER Canada Inc., and the Cancer Research Fund of the Ontario Institute for Cancer Research (grant number 02-may-0159 to AMP).

Received: 15 September 2015 Accepted: 1 October 2015

Published online: 21 October 2015

References
Aigner J, Schneeweiss A, Sohn C, Marme F (2011) The role of neoadjuvant chemotherapy in the management of primary breast cancer. Minerva Ginecol 63(3):261–274
Ammann J, Cooke A, Trowsdale J (2013) Butyrophilin Bttn2a2 inhibits TCR activation and phosphorylation of Akt pathway signaling and induces Foxp3 expression in T lymphocytes. J Immunol 190(10):5030–5036
Araki T, Milbrandt J (2000) Ninjurin2, a novel homophilic adhesion molecule, is expressed in mature sensory and enteric neurons and promotes neurite outgrowth. J Neurosci 20(1):187–195
Benusiglio PR, Pharoah PD, Smith PL, Lesueur F, Conroy D, Luben RN, Dew G, Jordan C, Dunning A, Easton DF, Ponder BA (2006) HapMap-based study of the 17q21 ERBB2 ampliclon in susceptibility to breast cancer. Br J Cancer 95(12):1689–1695
Biaoxue R, Xiling J, Shuanying Y, Wei Z, Xiguang W, Jinsui S, Min Z (2012) Uregulation of Hsp90-beta and annexin A1 correlates with poor survival and lymphatic metastasis in lung cancer patients. J Exp Clin Cancer Res 31:70
Bouquey M, De Plaen E, Locker M, Poliard A, Mouillet‑Richard S, Boon T, Keller‑Negri E, Keller‑Hopfgartner G, Jordan C, Dunning A, Easton DF, Ponder BA (2006) HapMap‑based study of the 17q21 ERBB2 ampliclon in susceptibility to breast cancer. Br J Cancer 95(12):1689–1695
Campbell KA, Minashima T, Zhang Y, Hadley S, Lee YY, Gionvino J, Quirno M, Kirsch T (2013) Annexin A6 interacts with p65 and stimulates NF‑kappaB activity and catabolic events in articular chondrocytes. Arthritis Rheum 65(12):3120–3129
Cagnoni G, Tamagnone L (2014) Semaphorin receptors meet receptor tyrosine kinases on the way of tumor progression. Oncogene 33(40):4795–4802
Carey LA, Winer EP (2014) Defining success in neoadjuvant breast cancer trials. Lancet 384(9938):115–116
Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, Ollila DW, Sartor CI, Graham ML, Perou CM (2007) The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 13(8):2329–2334
Chia S, Swain SM, Byrd DR, Pollock DA, Mankoff DA (2008) Locally advanced and inflammatory breast cancer. J Clin Oncol 26(5):786–790
Coon JS, Marcus E, Gupta-Burt S, Seelig J, Jacobson K, Chen S, Renta V, Fronda G, Pressler HD (2002) Amplification and overexpression of topoisomerase llalpha predict response to anthracycline-based therapy in locally advanced breast cancer. J Clin Oncol 20(13):3291–3299
Costanzo P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, Bonnelye H, Cameron D, Gianni L, Valagussa P, Swain SM, Prowsell T, Loibl S, Wickerham DL, Bogaerts J, Baselga J, Perou C, Blumenthal G, Blihmmer J, Marmounas EP, Bergh J, Semiglazov V, Justice R, Edtmann H, Paik S, Piccart M, Snidhara R, Fasching PA, Slaets L, Tang S, Geyer B, Geyer CE Jr, Pazdur R, Ditsch N, Rastogi P, Eiermann W, von Minckwitz G (2014) Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384(9938):164–172

Additional file 1. Additional methods and clinical trial data.
